Voyager Therapeutics Current Ratio 2014-2018 | VYGR

Voyager Therapeutics current ratio from 2014 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Voyager Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.18B $0.03B 6.08
2018-06-30 $0.20B $0.03B 6.88
2018-03-31 $0.22B $0.03B 7.13
2017-12-31 $0.17B $0.02B 10.81
2017-09-30 $0.13B $0.02B 6.12
2017-06-30 $0.15B $0.01B 12.23
2017-03-31 $0.16B $0.01B 14.56
2016-12-31 $0.18B $0.01B 12.95
2016-09-30 $0.19B $0.02B 9.96
2016-06-30 $0.21B $0.02B 10.40
2016-03-31 $0.21B $0.02B 8.91
2015-12-31 $0.20B $0.02B 8.19
2015-09-30 $0.11B $0.02B 4.65
2015-06-30 $0.00B $0.00B 0.00
2015-03-31 $0.00B $0.00B 0.00
2014-12-31 $0.01B $0.00B 3.38
2014-09-30 $0.00B $0.00B 0.00
2014-06-30 $0.00B $0.00B 0.00
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.03
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.355B $0.010B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.676B 8.40
Teva Pharmaceutical Industries (TEVA) Israel $17.694B 6.11
Mylan (MYL) United Kingdom $16.304B 6.71
Bausch Health Cos (BHC) Canada $8.412B 5.98
Dr Reddy's Laboratories (RDY) India $5.939B 23.69
Supernus Pharmaceuticals (SUPN) United States $1.968B 18.64
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.768B 2.95
Amphastar Pharmaceuticals (AMPH) United States $1.134B 123.05
Homology Medicines (FIXX) United States $0.930B 0.00
CymaBay Therapeutics (CBAY) United States $0.593B 0.00
Assembly Biosciences (ASMB) United States $0.541B 0.00
Akorn (AKRX) United States $0.507B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.307B 0.00
Sol-Gel Technologies (SLGL) Israel $0.122B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.086B 0.00
Teligent (TLGT) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.054B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.004B 0.00